BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.75 CHF | -2.86% |
|
+0.74% | +15.44% |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
| Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Chart calendar Basilea Pharmaceutica AG
cccb4e8d99805079e8ddfef7ae0825f.Hvl0_z9SuLh4q0YlHC5HOcY3XR4NwAwqJ20u51Gx248.SrwYl3Nqyc9NmR5NKH0Mc6d9aHI682JjFTtjoTX99uQrpiG1UxyI0QjRAw~54340e605b701898f43b0c0f5d5d92e0
Upcoming events on Basilea Pharmaceutica AG
Past events on Basilea Pharmaceutica AG
| 2024-03-20 | Kepler Cheuvreux Swiss Seminar |
| 2024-02-13 10:00 am | Q4 2023 Earnings Call |
| 2024-02-13 01:15 am | Q4 2023 Earnings Release |
| 2024-01-09 | Baader Helvea Swiss Equities Conference |
| 2024-01-07 | Edison Healthcare Week |
| 2023-11-13 | Jefferies London Healthcare Conference |
| 2023-11-13 10:00 am | Business Update Call |
| 2023-10-10 | IDWeek Conference - Abstract No:1946 |
| 2023-10-10 | IDWeek Conference - Abstract No:2162 |
| 2023-10-10 | IDWeek Conference - Abstract No:2561 |
| 2023-10-10 | IDWeek Conference - Abstract No:2531 |
| 2023-10-10 | IDWeek Conference - Abstract No:2530 |
| 2023-10-10 | IDWeek Conference - Abstract No:2532 |
| 2023-10-10 | IDWeek Conference - Abstract No:2173 |
| 2023-10-10 | IDWeek Conference - Abstract No:2785 |
| 2023-09-24 | HBM Biopharma Summit |
| 2023-09-13 | Pareto Securities' Healthcare Conference |
| 2023-09-10 | Morgan Stanley Global Healthcare Conference |
| 2023-09-10 | H.C. Wainwright Global Investment Conference |
| 2023-08-15 10:00 am | Q2 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CHF | Released Forecast Spread | 134 133 0.77% | 128 131 -2.39% | 148 145 2.41% | 148 122 21.38% | 158 156 0.97% | 182 |
|
EBITDA Million CHF | Released Forecast Spread | -15,6 -23,5 33.65% | -22,1 -21,5 -2.73% | 1,93 -13,4 114.36% | 19,6 -4,21 566.99% | 20,8 15,8 31.62% | 33,0 |
|
EBIT Million CHF | Released Forecast Spread | -17,2 -26,4 34.82% | -8,22 -11,2 26.47% | 1,20 -13,0 109.26% | 18,5 -4,80 485.36% | 19,2 14,8 29.78% | 30,9 |
|
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | -22,4 -31,3 28.5% | -14,7 -16,4 10.59% | -6,80 -22,2 69.37% | 12,1 -13,9 187.12% | 10,5 5,36 95.31% | 22,7 |
|
Net income Million CHF | Released Forecast Spread | -22,4 -32,1 30.12% | -14,7 -16,4 10.35% | -6,80 -20,7 67.07% | 12,1 -13,9 187.38% | 10,5 5,35 96.21% | 21,8 |
|
EPS CHF | Released Forecast Spread | -2,08 -2,88 27.71% | -1,43 -1,52 6.13% | -0,58 -1,83 68.22% | 1,02 -1,35 175.67% | 0,86 0,43 101.28% | 1,93 |
| Announcement Date | 18/02/20 | 16/02/21 | 15/02/22 | 14/02/23 | 13/02/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CHF | Released Forecast Spread | 71,2 70,2 1.36% | 69,3 63,0 9.96% | 58,3 60,2 -3.07% | 54,2 58,7 -7.67% | 93,9 | 58,6 42,4 38.32% | 89,2 56,2 58.64% | 83,8 | 84,9 64,7 31.15% | 72,7 72,0 0.95% | 85,9 | 95,3 |
|
EBITDA Million CHF | Released Forecast Spread | -16,9 -22,0 23.32% | 12,9 | 18,0 | |||||||||
|
EBIT Million CHF | Released Forecast Spread | -4,00 -10,3 61% | 12,8 -14,9 186.04% | -21,0 -25,6 17.83% | -15,4 -13,5 -14.5% | 16,6 3,60 361.11% | -9,04 -15,7 42.41% | 27,5 -7,85 450.84% | 36,9 13,1 182.4% | -17,7 -21,7 18.28% | 15,0 | 15,0 | |
|
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | -6,97 -13,6 48.77% | 9,97 -14,2 170.07% | -24,6 -29,9 17.59% | -19,9 -10,8 -84.05% | 13,1 0,80 1535.25% | -12,2 -18,3 33.22% | 24,3 -9,80 348.19% | 31,9 10,3 209.39% | -21,4 -26,3 18.61% | 12,4 | 14,6 | |
|
Net income Million CHF | Released Forecast Spread | -7,00 -13,6 48.55% | 9,90 -14,4 168.92% | -24,7 -29,9 17.52% | -19,9 -10,8 -84.26% | 13,1 0,80 1537.5% | -12,2 -18,3 33.28% | 24,4 -9,80 348.53% | 31,8 8,73 264.12% | -21,3 -26,0 18.15% | 11,7 | 13,4 | |
|
EPS CHF | Released Forecast Spread | -0,64 -1,23 47.83% | 0,91 -1,29 170.82% | -2,34 -2,62 10.69% | -1,84 -1,01 -82.18% | 1,26 0,07 1700% | -1,03 -1,55 33.55% | 2,05 -0,82 350% | 2,42 0,73 231.51% | -1,56 -2,05 23.72% | 0,94 | 1,05 | |
| Announcement Date | 18/02/20 | 11/08/20 | 16/02/21 | 17/08/21 | 15/02/22 | 16/08/22 | 14/02/23 | - | 15/08/23 | 13/02/24 | - | - |
More events
Past sector events for Basilea Pharmaceutica AG
| 2024-04-17 | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BSLN Stock
- Calendar Basilea Pharmaceutica AG
